Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Studies gene changes in prostate cancer patients after radiation treatment fails

Observes whether two gene changes predict outcomes in men with prostate cancer after treatment.

Plain-language title generated from the registry record
Registry title: The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

Key facts

Where
Chicoutimi, Greenfield Park, Laval, Montreal, Québec, Sherbrooke, and Trois-Rivières, CanadaSee the 9 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with high-risk prostate cancer whose PSA rose again after radiation treatment and who are treated first with an LHRH agonist.

Age
18 years or older.
Sex
Men only.
Disease stage
High-risk prostate cancer: T3a or higher, PSA above 20, Gleason score 8 or higher.
Earlier treatment
Biochemical failure (rising PSA) after salvage or radical radiation therapy. First treatment with an LHRH agonist.
Biomarker or test result
The study looks at the TMPRSS2-ERG gene fusion and PTEN. The record does not say a specific result is required.

Read by machine on 9 November 2026.

Where in Canada

  • CIUSSS du Saguenay-Lac-St-Jean/CSSS de ChicoutimiChicoutimi, CanadaTaking people
  • CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyneGreenfield Park, CanadaTaking people
  • CISSS de Laval - Hôpital de la Cité-de-la-santé de LavalLaval, CanadaTaking people
  • CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve RosemontMontreal, CanadaTaking people
  • Jewish General Hospital, McGill UniversityMontreal, CanadaTaking people
  • MUHC - Cedars Cancer CenterMontreal, CanadaTaking people
  • CHU - L'Hôtel-Dieu de QuébecQuébec, CanadaTaking people
  • CIUSSS de l'Estrie - Hôpital FleurimontSherbrooke, CanadaNot yet recruiting
  • CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-RivièresTrois-Rivières, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sir Mortimer B. Davis - Jewish General Hospital
Trial code
NCT02573636
Record updated
4 December 2024
Original description
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.Read full original descriptionShow less

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.

Inclusion: T3a +; PSA > 20; Gleason 8 or higher; Karnofsky performance status ≥ 70; Signed study-specific informed consent.

Exclusion: -.

ClinicalTrials.gov NCT02573636